tbuckley/cabot-search huggingface dataset:
Abstract 17106: Nox2-derived Reactive Oxygen Species Impede Vascular Repair in the Context of Endothelium-specific Insulin Resistance
Authors: Noman Ali, Nadira Yuldasheva, Anshuman Sengupta, Jessica Smith, Andrew Walker, Anna Skromna, Natalia Makava, Stacey Galloway, Peysh Patel, Ben Mercer, Stephen Wheatcroft, Mark Kearney, Richard Cubbon
Journal: Circulation (2015)

Introduction: Insulin resistance is independently linked to cardiovascular disease, and oxidative stress is recognised as a potential contributor to this relationship. We have previously shown that endothelium-specific insulin resistance promotes endothelial dysfunction, atherosclerosis, and increased vascular NADPH oxidase 2 (NOX2) derived reactive oxygen species (ROS). Oxidative stress may promote vascular disease by impairing endogenous vascular repair. Hypothesis: We hypothesise that deletion of NOX2 in mice with endothelial specific insulin resistance can improve vascular repair. Methods: Mice with endothelial specific insulin resistance (ESMIRO) were bred with mice deficient in NOX2, in order to produce double-cross ESMIRO x NOX2y/- (ExN) offspring. Phenotypic assessment comprised glucose and insulin tolerance tests and ELISA for plasma insulin concentration. In vivo assessment of vascular repair and angiogenesis were undertaken using femoral artery wire injury and hindlimb ischaemia techniques, respectively, whilst flow cytometry was used to quantify circulating progenitor cells (CPCs). Data are expressed as mean [standard error] and compared using unpaired t-tests; *=p&lt;0.05. Results: No significant differences were seen between ExN and ESMIRO in glucose tolerance, insulin sensitivity, or basal insulin level (0.8[0.1]ng/ml vs. 0.8[0.1];p=0.8). ExN mice demonstrated significantly improved vascular regeneration following injury compared to ESMIRO (62%[4%] vs. 46%[3%]*), coupled with a significantly higher number of CPCs (202.6[20.3] per 100000 lymphocytes vs. 134.3[10.6]*). This improvement was not mirrored in ischaemic limb perfusion recovery (Perfusion relative to non-ischaemic limb at 28 days 54%[8%] vs. 53%[4%]). Conclusions: Our data demonstrate that targeting NOX2 can augment vascular repair in the setting of endothelial specific insulin resistance, whilst having no detrimental impact on the response to limb ischaemia, and is associated with an increased abundance of CPCs. These findings support a possible role for NOX2 inhibitors to promote recovery from vascular injury in the setting of insulin resistance.
P2.03b-097 Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: Katharina Verleger, Maarten Treur, John Penrod, Melinda Daumont, Michael Lees, Cynthia Macahilig, Caitlyn Solem, Shan Jiang, Oana Chirita, Nadine Hertel
Journal: Journal of Thoracic Oncology (2017)
Syntactic levels, lexicalism, and ellipsis: The jury is still out
Authors: Robert J. Hartsuiker, Sarah Bernolet
Journal: Behavioral and Brain Sciences (2017)

Abstract Structural priming data are sometimes compatible with several theoretical views, as shown here for three key theoretical claims. One reason is that prime sentences affect multiple representational levels driving syntactic choice. Additionally, priming is affected by further cognitive functions (e.g., memory). We therefore see priming as a useful tool for the investigation of linguistic representation but not the only tool.
Advance care planning in community: Evaluation of a two-session workshop.
Authors: Michael Rabow, Marilyn McGowan, Rebecca Small, Redwing Keyssar, Hope S. Rugo
Journal: Journal of Clinical Oncology (2017)

14 Background: Engaging patients in advance care planning (ACP) is challenging. Group visits and multiple patient-clinician interactions appear to promote advance directive (AD) completion. We evaluated the effectiveness of a two-session ACP workshop. Methods: We conducted a nurse-led ACP workshop for patients and their family caregivers in a comprehensive cancer center. Patients were invited by their outpatient palliative care physician and an assistant helped coordinate attendance. Monthly sessions were 2 hours long and 2 weeks apart. The first session detailed the ACP process, featured the “Go Wish” card game, and introduced the “Five Wishes” AD. In the time between sessions, patients were encouraged to play Go Wish with family and to begin filling out their AD. The second session included questions and discussion, and helped patients complete, notarize, and scan their AD into the EMR. Workshop evaluation included the validated 4-question Sudore ACP Readiness Survey as well as semi-structured participant interviews. Results: Ten of 11 participants from 4 workshop offerings completed surveys. Median age was 48 years (range 41-72). Most patients (10/11, 90.9%) had breast cancer. Mean pre-workshop ACP readiness was 4.0 out of 5; post-workshop readiness increased nearly significantly to 4.325 (p = .057). Eight of the workshop participants (72.7%) had a new notarized AD scanned into the EMR. Participants most appreciated the chance to talk with other patients (“The most important thing was having a group there. I don’t think I ever would have read that packet if it had just been handed to me.”) and the chance to include their family caregivers (“My family and I had a rich and bonding talk, which was helpful for their own thinking about the AD for themselves as well.”). Two family caregivers completed their own AD. Patients who declined a workshop invitation most commonly reported they “did not have time” because of medical appointments. Conclusions: The ACP workshop was well received by participants and increased ACP readiness, discussion, and completion. The opportunities for group discussion and inclusion of family caregivers were important to participants. Barriers to attending workshops must be explored.
PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
Authors: S. Murakami, M. Özgüroğlu, A. Villegas, D. Daniel, D.V. Baz, R. Hui, T. Yokoi, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, H. Jiang, Y. Huang, P.A. Dennis, S.J. Antonia
Journal: Annals of Oncology (2017)
Abstract 233: DJ-1 Gene Therapy Opposes the Development of Ischemic Heart Failure
Authors: Yuuki Shimizu, Di Sha, Lih-Shen Chin, Lian Li, John Calvert
Journal: Circulation Research (2016)

Background: DJ-1 is a cytoprotective protein that is activated in response to various pathological stimuli. The ability of DJ-1 to perform its cellular actions is dependent on a conformational change, as evidenced by previous findings that it is cleaved by oxidative stress and that this cleavage activates its cytoprotective function. Previously, we demonstrated that the loss of functional DJ-1 lead to the enhancement of myocardial infarction and exacerbation of cardiac dysfunction following the onset of acute myocardial ischemia-reperfusion (I/R) injury. Currently, it is not known if the gain of functional DJ-1 has cardioprotective effects. Here, we investigated if the delivery of the cleaved form of DJ-1 using a gene therapy approach protected against the development of ischemic-induced heart failure. Methods and Results: We generated a viral vector to express the active form of DJ-1 (AAV9-DJ1WTΔC). To test the efficiency, specificity, and dose-dependence of AAV9-mediated transduction, we injected increasing doses of AAV9-GFP into the femoral vein of mice. A dose-dependent increase in GFP levels was observed in the heart and our analysis found that the 2x10 11 vg/mL dose achieved maximal delivery to the heart with minimal delivery to other tissue. GFP-stained sections of heart indicated that a substantial proportion of cardiomyocytes expressed the transduced gene. Next, we evaluated the protein expression of the full-length and active form of DJ-1 2 weeks after the administration of AAV9-DJ1WTΔC. No changes in the expression of the full-length form of DJ-1 were observed, but a 2-fold increase in the active form of DJ-1 was observed. Finally, mice administered AAV9-DJ1WTΔC displayed significant less left ventricular dilatation, left ventricular dysfunction, and hypertrophy compared to the AAV9-Empty treated following mice 60 minutes of myocardial ischemia and 4 weeks of reperfusion. Conclusion: These results indicated that DJ-1 is an endogenous cytoprotective protein that protects against the development of ischemic heart failure. Importantly, these results demonstrate the feasibility of using a gene therapy approach to deliver the cleaved form of DJ-1 to the heart as a therapeutic strategy to protect against ischemic heart disease.
Antipsychotic Drug Prescribing in Nursing Homes
Authors: Juanita L. Westbury
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidémiologie descriptive des exanthèmes dans la région de Rotterdam, janvier 1997 à juin 1998
Authors: F Termorshuizen, M J W van de Laar
Journal: Eurosurveillance (1998)

Le Conseil Europeen sur la Vaccination a emis des recommandations visant a l’elimination de la rougeole en Europe d’ici 2007 (1), objectif approuve par les directeurs des programmes nationaux de vaccination de la region Europe de l’Organisation Mondiale de la Sante (OMS). Dans ce contexte, l'etude de l’epidemiologie des exanthemes (rougeurs/eruptions cutanees associees a de la fievre) est importante. La rougeole, autrefois la forme la plus courante d’exantheme chez les enfants en Europe, est de plus en plus rare avec l’augmentation de la couverture vaccinale.
Can Exercise Prevent Knee Osteoarthritis?
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J)
Authors: T. Hase, S. Takeuchi, M. Ando, A. Hata, H. Kenmotsu, T. Fujiwara, S. Shimizu, K. Nagase, K. Yoshimura, N. Katakami, T. Takahashi, Y. Hasegawa, S. Yano
Journal: Annals of Oncology (2017)
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial
Authors: Antonia K Roseweir, Lindsay Bennett, Ashley Dickson, Kelvin Cheng, Mary-Anne Quintayo, Jane Bayani, Donald C McMillan, Paul G Horgan, Cornelis J H van de Velde, Caroline Seynaeve, Annette Hasenburg, Dirk G Kieback, Christos Markopoulos, Luc Y Dirix, Daniel W Rea, Elizabeth A Mallon, John M S Bartlett, Joanne Edwards
Journal: JNCI Journal of the National Cancer Institute (2017)

Aromatase inhibitors improve disease-free survival compared with tamoxifen in postmenopausal women with hormone receptor-positive breast cancer. The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial compared exemestane monotherapy with sequential therapy of tamoxifen followed by exemestane. The trial failed to show a statistically significant difference between treatment arms. A robust translational program was established to investigate predictive biomarkers.A tissue microarray was retrospectively constructed using a subset of patient tissues (n = 4631) from the TEAM trial (n = 9766). Immunohistochemistry was performed for biomarkers, classed into three groups: MAPK pathway, NF-kappa B pathway, and estrogen receptor (ER) phosphorylation. Expression was analyzed for association with relapse-free survival (RFS) at 2.5 and 10 years and treatment regimen using Kaplan-Meier curves and log-rank analysis. All statistical tests were two-sided.In univariate analysis, ER167 (hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.59 to 0.85, P < .001), IKKα (HR = 0.74, 95% CI = 0.60 to 0.92, P = .005), Raf-1338 (HR = 0.64, 95% CI = 0.52 to 0.80, P < .001), and p44/42 MAPK202/204 (HR = 0.77, 95% CI = 0.64 to 0.92, P = .004) were statistically significantly associated with improved RFS at 10 years in patients receiving sequential therapy. Associations were strengthened when IKKα, Raf-1338, and ER167 were combined into a cumulative prognostic score (HR = 0.64, 95% CI = 0.52 to 0.77, P < .001). Patients with an all negative IKKα, Raf-1338, and ER167 score favored exemestane monotherapy (odds ratio = 0.56, 95% CI = 0.35 to 0.90). In multivariable analysis, the IKKα, Raf-1338, and ER167 score (P = .001) was an independent prognostic factor for RFS at 10 years in patients receiving sequential therapy.The IKKα, Raf-1338, and ER167 score is an independent predictive biomarker for lower recurrence on sequential therapy. Negative expression may further offer predictive value for exemestane monotherapy.
Abstract 18373: Electrocardiographic Intrinsicoid Deflection and Incident Congestive Heart Failure: The Multi-ethnic Study of Atherosclerosis (MESA)
Authors: Wesley T O'Neal, Waqas T Qureshi, Saman Nazarian, Nadine Kawel-Boehm, David A Bluemke, Joao A Lima, Elsayed Z Soliman
Journal: Circulation (2015)

Introduction: Intrinsicoid deflection (ID), the time to R wave peak on the electrocardiogram, represents delayed ventricular activation which possibly denotes impaired myocardial function. We hypothesized that delayed ID is predictive of future heart failure events. Methods: A total of 6,394 (mean age 62 ± 10; 54% women; 38% whites; 28% blacks; 22% Hispanics; 12% Chinese-Americans) participants without clinically apparent cardiovascular disease or major ventricular conduction delay (QRS ≥120 ms) from the Multi-Ethnic Study of Atherosclerosis (MESA) were included. ID was automatically measured from baseline electrocardiograms (2000-2002) as the maximum ID time in leads V5 and V6. Cox proportional hazards regression was used to compute hazard ratios (HR) and 95% confidence intervals (95%CI) for the association between ID and heart failure. Results: Over a median follow-up of 11.2 years, a total of 217 (3.4%) participants developed heart failure (incidence rate per 1000 person-years=3.33, 95%CI=2.91, 3.80). In a multivariable Cox regression analysis adjusted for demographics, cardiovascular risk factors, and potential confounders, each 10 ms increase in maximum ID was associated with an increased risk for heart failure (HR=1.42, 95%CI=1.15, 1.74). The results remained similar when stratified by age, sex, and race/ethnicity. Conclusions: Delayed ID is able to identify individuals at risk for developing heart failure before major conduction delays (e.g., bundle branch block) are evident.
Prognostic gene expression signature in chemotherapy treated patients from the MAGIC trial
Authors: E.C. Smyth, G. Nyamundanda, D. Cunningham, I.B. Tan, E. Fontana, C. Ragulan, A.F. Okines, S. Lin, A. Wotherspoon, M. Nankivell, C. Peckitt, N. Valeri, R.E. Langley, P. Tan, A. Sadanandam
Journal: Annals of Oncology (2017)
P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC
Authors: Vikas Talreja, Vanita Noronha, Vijay Patil, Amit Joshi, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Supriya Goud, Sucheta More, Ashay Karpe, Anant Ramaswamy, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Kumar Prabhash
Journal: Journal of Thoracic Oncology (2017)
Sex Differences in Health Care Utilization, End‐Stage Renal Disease, and Mortality Among Medicaid Beneficiaries With Incident Lupus Nephritis
Authors: Candace H. Feldman, Anna Broder, Hongshu Guan, Jinoos Yazdany, Karen H. Costenbader
Journal: Arthritis & Rheumatology (2017)

While systemic lupus erythematosus and lupus nephritis (LN) disproportionately affect females, previous studies suggest that males may experience poorer outcomes. We undertook this study to investigate sex differences in health care utilization, end-stage renal disease (ESRD), and mortality among patients with LN receiving Medicaid, public insurance for low-income individuals.
P2.07-016 Inmunotherapy: Which Is More Important, Choosing Patients Who Will Respond or Identifying Those Who Will Die Early?
Authors: I. García, M. Berciano, M. Dominguez, J. Baena, A. Godoy, L. Pérez, L. Galvez, M. Robles, T. Redondo, C. Quero, M.I. Sáez, M. Trigo
Journal: Journal of Thoracic Oncology (2017)
Prospective assessment of symptom burden interfering with decision making during the end-of-life phase of high-grade glioma patients.
Authors: Tobias Walbert, Lonnie Schultz, Joel Phillips
Journal: Journal of Clinical Oncology (2017)

90 Background: To date it is unclear when patients with high grade glioma (HGG) lose their capacity to make decisions during the end-of-life (EoL) phase. EoL symptoms have not been prospectively assessed. The goal of this prospective single center study was to assess the symptom burden in terminal HGG patients with a special focus on symptoms related to decision making capacity during the last 3 months of life. Methods: Patients with HGG, failing 3 rd line therapy, showing clinical and/or radiological progression with a Karnofsky Performance Status score &lt; 60 were eligible for enrollment. A baseline MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) was performed upon enrollment. Patients or surrogates received bi-weekly telephone calls to repeat the MDASI-BT. Calls continued until death, or refusal to participate. Symptoms were stratified by weeks prior to death. Mixed models were used to assess for symptom and interference changes over time. Overall time effect was tested at the 0.05 level. If significant, pairwise comparisons of the time groups were done. Testing level was set at 0.01 to take into account the large number of comparisons. Results: Symptom scores of 52 patients are available for analysis. Symptoms involved in decision making such as speaking, concentrating, drowsiness (all p &lt; 0.001), and understanding (p &lt; 0.011) started to decline severely 12 weeks prior to death. The cognitive construct (understanding, remembering, speaking, concentrating) was significantly impaired during the last 2 weeks of life and started to deteriorate after week 12 (p &lt; 0.001). The decision making composite score (understanding, speaking, concentrating, fatigue, drowsiness) showed the same pattern (p &lt; 0.001). Overall disease burden also significantly increases within the last 2 weeks of death. Conclusions: Patients with HGG have a high symptom burden during the active EoL phase, increasing significantly during the last 12 weeks prior to death. Symptoms interfering with decision making capacity increase after week 12 and reach their peak 2 weeks prior to death. These findings stress the importance of early initiation of palliative care and advance care planning in patients with HGG.
Avoiding frostbite: It helps to learn from others
Authors: Michael Henry Tessler, Noah D Goodman, Michael C Frank
Journal: Behavioral and Brain Sciences (2017)

Abstract Machines that learn and think like people must be able to learn from others. Social learning speeds up the learning process and – in combination with language – is a gateway to abstract and unobservable information. Social learning also facilitates the accumulation of knowledge across generations, helping people and artificial intelligences learn things that no individual could learn in a lifetime.
Multidisciplinary osteoncologic approach to bone metastases: Analysis of a large, mono-institutional cohort.
Authors: Marco Maruzzo, Selma Ahcene Djaballah, Antonella Brunello, Cristina Falci, Stefania Zovato, Stefania Schiavon, Ugo Nena, Sara Galuppo, Alessandro Parisi, Camillo Aliberti, Pietro Ruggieri, Vittorina Zagonel
Journal: Journal of Clinical Oncology (2017)

159 Background: Bone metastases are responsible for high morbidity in patients (pts) with a strong clinical impact. Recently, a new multidisciplinary approach called osteoncology has benn develped. No data on multidisciplinary management of large series of patients (pts) with bone cancer disease are available. Methods: We reviewed clinical data of all the consecutive pts evaluated from Apr 2013 to Dec 2016 in the multidisciplinary Osteoncology clinic of Istituto Oncologico Veneto. We collected clinical data on primary diasease, sites of disease, pain, bone clinical and radiological situation, assesment and medical decision taken in a multidisciplinary team. Results: 481 pts (303 F, 63%) have been evaluated by a multidisciplinary team composed by medical and clinical oncologist, pain specialist, endocrinologist, radiologist and ortopedic surgeon. Totally, 444 visits and 340 discussione have been performed. 422 pts (88%) had bone metastases, median age 65 years (range 34-89). 388 pts (92%) had vertebral metastases, 167 (39%) had pelvic bone disease, 201 (47%) had other site of bone disease including extremities. 186 (39%) pts had pain. We have prescribed a corset for 151 (31%) pts, radiation therapy for 202 (42%) pts with a median time from prescription to delivery of 15 days. Vertebroplastic has been prescribed in 66 (14%) pts with a median time for delivery of 7.5 days. 33 (7%) pts received indication to orthopedic surgery with a median waiting time of 15 days. For 115 pts data on pain at visit and 30 days later were available: 41 pts had no change in NRS, 11 pts had a worst paint (median NRS Δ = +2), 63 pts had a pain reduction (median NRS Δ = -3). 301 pts received a diagnosis of SRE. Median OS (mOS) was 80.9 months; at 2 yrs 91% of M0 pts vs 75.8% of M1 pts was alive (p = 0.0018); mOS for pts with a SRE was 70 vs 89.5 mos in pts without SRE (p = 0.033); among M1 pts, there was no significant difference from having or not a SRE. Conclusions: To our knowledge this is the first reported series of pts evalutated by an osteoncologic team. OS confirms that pts with SRE had a poorer outcome. Median time from prescrition to care delivery is shorter from data available in literature, conferming the positive impact for pts from multidisciplinary approach.